Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of **autologous platelet-rich plasma (PRP)** and **cross-linked hyaluronic acid (HA)**, used primarily as an **injectable regenerative treatment** for degenerative joint disorders (such as osteoarthritis) and for various types of skin fibrosis and tissue repair. Platelet-rich plasma is derived from the patient's own blood and contains a high concentration of platelets that release growth factors promoting tissue healing, angiogenesis, and anti-inflammatory effects. Cross-linked hyaluronic acid is a modified polymer of naturally-occurring hyaluronic acid, designed for increased viscosity and longevity in tissues, serving as a space-filling, lubricating, and moisturizing agent. When combined, this mixture aims to both stimulate endogenous repair (via PRP’s growth factor release) and physically cushion/lubricate tissues (via HA’s viscoelastic/space-filling properties), yielding synergistic improvements in joint function and tissue elasticity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous platelet-rich plasma + cross-linked hyaluronic acid.